Hologic (NASDAQ:HOLX) Releases Q2 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its second quarter 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.000-1.030 for the period, compared to the consensus estimate of 1.040. The company issued revenue guidance of $995.0 million-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Stock Up 1.7 %

HOLX stock traded up $1.22 during trading on Wednesday, hitting $72.80. 2,779,067 shares of the stock traded hands, compared to its average volume of 2,293,025. Hologic has a 1 year low of $68.61 and a 1 year high of $84.67. The firm’s 50 day moving average is $73.05 and its two-hundred day moving average is $77.98. The stock has a market cap of $16.43 billion, a price-to-earnings ratio of 21.86, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. On average, sell-side analysts anticipate that Hologic will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Monday, January 13th. Royal Bank of Canada raised their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a report on Monday. Finally, BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Eight investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $88.92.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.88% of the stock is owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.